However, other mediators may also contribute to the progression of hepatitis; therefore, the presented PK/PD/disease progression model should be further developed and include the assessment of the expression of other inflammatory cytokines and especially chemokines at the gene and protein levels as well as other biomarkers of liver damage (gamma-glutamyl transpeptidase and alkaline phosphatase), liver function (e.g., bilirubin concentration in the blood or prothrombin time), and liver fibrosis. The gene discussed is GGTLC1; the disease is Hepatic fibrosis.